Virtu Financial LLC Curis Inc Transaction History

Virtu Financial LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 27, 2023	BUY	$0.57 - $0.99 $5,959 - $10,350	10,455 New	10,455 $9,000
Q4 2022 Feb 15, 2023	BUY	$0.47 - $17.22 $43,704 - $1.6 Million	92,989 New	92,989 $51,000
Q2 2022 Aug 09, 2022	BUY	$0.71 - $2.43 $35,321 - $120,887	49,748 Added 235.77%	70,848 $70,000
Q1 2022 May 17, 2022	BUY	$2.31 - $5.13 $24,793 - $55,060	10,733 Added 103.53%	21,100 $50,000
Q4 2021 Feb 17, 2022	BUY	$4.45 - $8.09 $46,133 - $83,869	10,367 New	10,367 $49,000
Q3 2021 Nov 12, 2021	SELL	$6.94 - $8.85 $144,018 - $183,655	-20,752 Closed	0 $0
Q2 2021 Sep 17, 2021	BUY	$7.45 - $16.27 $154,602 - $337,635	20,752 New	20,752 $167,000
Q2 2020 Aug 07, 2020	SELL	$0.63 - $1.7 $18,889 - $50,971	-29,983 Closed	0 $0
Q4 2019 Feb 04, 2020	BUY	$1.36 - $2.44 $40,776 - $73,158	29,983 New	29,983 $51,000
Q1 2019 Apr 12, 2019	SELL	$0.78 - $2.01 $10,678 - $27,516	-13,690 Closed	0 $0
Q4 2018 Jan 16, 2019	BUY	$0.62 - $2.25 $8,487 - $30,802	13,690 New	13,690 $9,000

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $409M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.